Lifetime Management in Low- And Intermediate-Risk TAVI: Insights on Navitor and the VANTAGE Data
-
4m 20s
-
7m 27s
In this interview, Prof Van Mieghem emphasises the need for safety, durability, optimal haemodynamics and future coronary access when treating low- and intermediate-risk TAVI patients. He highlights Navitor™’s resheathable design, intra-annular function, large-cell frame for coronary re-access and dual sealing cuff to minimise paravalvular leak. Reviewing the VANTAGE trial, he notes very low one-year mortality and disabling stroke, no moderate or severe PVL and excellent valve haemodynamics.
The recently presented VANTAGE trial showed excellent outcomes for TAVI in low- and intermediate-risk patients, with very low mortality, disabling stroke and paravalvular leak at one year. In this interview series, recorded at ESC 2025, Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL), Dr Marianna Adamo (University of Brescia, Brescia, IT) and Dr Birgid Gonska (Kerckhoff-Klinik, Bad Nauheim, DE) discuss how the data informs lifetime management in this growing patient group. The faculty stress the importance of minimising complications, ensuring valve durability, preserving coronary access and planning for future interventions. The experts highlight how the Navitor™ TAVI system supports these needs through its intra-annular design, resheathable platform, large-cell frame and dual sealing cuff.
Watch the series to hear their perspectives on valve choice, procedural planning and long-term strategy for lower-risk patients.
For further insights, watch the round table discussion, 'Expanding TAVI to Low- And Intermediate-Risk Patients'
More from this programme
Part 1
Insights from Prof Nicolas Van Mieghem
In this interview, Prof Van Mieghem emphasises the need for safety, durability, optimal haemodynamics and future coronary access when treating low- and intermediate-risk TAVI patients. He highlights Navitor™’s resheathable design, intra-annular function, large-cell frame for coronary re-access and dual sealing cuff to minimise paravalvular leak. Reviewing the VANTAGE trial, he notes very low one-year mortality and disabling stroke, no moderate or severe PVL and excellent valve haemodynamics.
Part 2
Insights from Dr Birgid Gonska
Dr Birgid Gonska stresses the importance of procedural safety, excellent haemodynamics, valve durability and preserved coronary access when treating younger, low- and intermediate-risk TAVI patients. She highlights Navitor™’s self-expanding, repositionable design, which supports precise implantation, reduces pacemaker and PVL risk and ensures reliable coronary re-access. On the VANTAGE trial data, Dr Gonska points to single-digit gradients, low complication rates and minimal PVL, confirming Navitor’s safety and value for lifetime management.
| 1 session | |
| Insights from Dr Birgid Gonska | Watch now |
Part 3
Insights from Dr Marianna Adamo
Dr Adamo discusses the importance of lifetime management in low- and intermediate-risk TAVI, focusing on minimising complications, ensuring valve durability and preserving coronary access for future interventions. She highlights Navitor™’s intra-annular design, favourable haemodynamics and ease of delivery, which support safe procedures and future re-interventions. Reviewing the VANTAGE trial, she notes 0% moderate or severe PVL at 30 days, 97% technical success and very low mortality and stroke at one year, confirming Navitor’s safety and effectiveness in this population.
| 1 session | |
| Insights from Dr Marianna Adamo | Watch now |
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved large bore closure devices. He works actively in expanding TAVI indications, most notably TAVI as a means to further unload the left ventricle in heart failure patients with moderate aortic stenosis (the TAVR UNLOAD trial). Prof Van Mieghem is also involved in the development and dispersion of mechanical circulatory support (MCS) devices as well as transcatheter mitral…
Marianna Adamo
Inteventional Cardiologist
Prof Marianna Adamo is an interventional cardiologist and heart failure physician, and Associate Professor at the University of Brescia, Italy. Her clinical and research interests focus on structural heart interventions, including transcatheter aortic valve implantation (TAVI), with particular emphasis on patient selection, procedural optimisation, and long-term outcomes. Prof Adamo is actively involved in international research collaborations and frequently contributes to leading cardiology congresses and publications.
Birgid Gonska
Interventional Cardiologist
Dr Birgid Gonska is an interventional cardiologist at Kerckhoff-Klinik in Bad Nauheim, Germany, specialising in the diagnosis and treatment of structural heart disease. Her clinical expertise includes the management of aortic regurgitation, aortic valve stenosis, and heart block, with advanced skills in pacemaker implantation and transcatheter aortic valve replacement (TAVR).
At Kerckhoff-Klinik, Dr Gonska is actively involved in patient care and clinical research, contributing to the development and refinement of minimally invasive therapies for complex valve disease. She has a particular interest in optimizing outcomes for patients with severe aortic valve pathology and conduction disorders, integrating evidence-based practice with state-of-the-art interventional techniques.